Dr. Rojas-Quintero is researching how Metformin, a long-used diabetes drug, may be able to slow fibrosis in the lungs.

OSA and COPD present with symptoms that often go undetected for too long. How can clinicians recognize symptoms faster?

The disappointing result means that AZ will be unable to follow in the footsteps of GSK, whose IL-5 inhibitor Nucala ...

An EHR-embedded inpatient care pathway for COPD was tied to improved adherence to evidence-based practices, shorter hospital ...

Saphnelo, which generated $304 million in sales in the first half of this year, is projected to achieve peak annual sales of ...

AstraZeneca (($AZN)) announced an update on their ongoing clinical study. AstraZeneca has launched a Phase II clinical study titled ‘A Phase II, ...

Achieve recently announced that the FDA accepted its cytisinicline New Drug Application for treatment of nicotine dependence for smoking cessation, with a PDUFA target action date of June 20, 2026.

Among patients with COPD, at least 50% reported that the disease impacts their daily life and emotional health, according to ...

While COPD (chronic obstructive pulmonary disease) symptoms may start out as mild to moderate — with episodes of difficulty breathing that come and go — over time, COPD tends to get worse, and many ...

AstraZeneca’s RESOLUTE phase III trial of Fasenra to treat chronic obstructive pulmonary disease fails to meet primary endpoint: Cambridge, UK Thursday, September 18, 2025, 15:0 ...